Therapy Detail

Therapy Name E7107
Synonym
Therapy Description

E7107 is a derivative of Pladienolide D, which inhibits assembly of the spliceosome specifically by binding to SF3B1, thereby inhibiting splicing of pre-mRNA and cell-cycle progression (PMID: 27622333).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
E7107 E7107 is a derivative of Pladienolide D, which inhibits assembly of the spliceosome specifically by binding to SF3B1, thereby inhibiting splicing of pre-mRNA and cell-cycle progression (PMID: 27622333).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
SF3B1 K700E hematologic cancer sensitive E7107 Preclinical - Cell culture Actionable In a preclinical study, mouse cells expressing SF3B1 K700E demonstrated sensitivity to E7107 in culture, resulting in decreased viability of cells (PMID: 27622333). 27622333
Unknown unknown Advanced Solid Tumor not applicable E7107 Phase I Actionable In a Phase I trial, E7107 treatment resulted in stable disease in 31% (8/26) of patients with advanced solid tumors, however, the study was discontinued due to vision loss in two patients (PMID: 24258465; NCT00499499). 24258465
Clinical Trial Phase Therapies Title Recruitment Status